The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

A lack of representation in genomic data has direct clinical consequences. A deep understanding of European genetics and a poor understanding of other groups has already manifested in less precise medical treatments for non-European populations, undermining the core promise of precision medicine.

Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.

Regeneron's focus on diverse populations is a core research strategy. Key discoveries, like the PCSK9 heart disease mutation, were only possible because they were significantly more common in African Americans. This proves that diverse genomic data unlocks unique and powerful therapeutic targets that would otherwise be missed.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

To scale its database from millions to tens of millions, Regeneron is moving beyond bespoke global studies. The new model involves large-scale partnerships with health systems and consumer data sources, using privacy-preserving tokenization to securely link genetic data with vast electronic health records.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.